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Background: The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune
diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children
with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the
presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of
JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood
as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers.
Methods: Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE
and 27 healthy controls) were determined by ELISA.
Results: The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1
and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum
HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same
inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to
hepatosplenomegaly or serositis in systemic onset JIA.
Conclusion: The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates
that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as
an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show
whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity.
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Juvenile idiopathic arthritis (JIA) is a heterogeneous
group of arthritis diseases with the onset before 16 years
of age and persistent for more than 6 weeks. Systemic
JIA (sJIA) is quite distinct from oligoarticular or polyar-
ticular subtypes with the prominence of systemic and in-
flammatory features [1]. At the initial presentation of* Correspondence: marija.jelusic.drazic@gmail.com
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unless otherwise stated.sJIA, arthritis may not be present. Hence, in children
with sJIA, the illness cannot be discriminated from sys-
temic infections by clinical or laboratory parameters. As a
result, early initiation of suitable antiinflammatory therapy
is difficult [2]. In the field of pediatrics, in addition to sJIA,
there is childhood SLE (cSLE) – is another acute inflam-
matory disorder frequently presenting a diagnostic and
therapeutic challenge. cSLE is a complex autoimmune in-
flammatory disease characterized by multiorgan involve-
ment. Approximately 20% of SLE cases begin before age
19 and often have a poor prognosis [3].td. This is an Open Access article distributed under the terms of the Creative
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unclear, a novel studies seem to point in the direction of
innate, rather than adaptive immune response [4,5]. As
shown during the past couple of decades, activation of
innate immune system seems to rely on a special class of
molecules, namely damage-associated molecular pat-
terns (DAMP) or alarmins [6-10]. A prototype of alar-
mins, high-mobility group box-1 (HMGB1), released to
the extracellular space from activated or necrotic cells,
acts as a key molecule of innate immunity [11,12]. Re-
cently, Garcia-Romo and collegues have demonstrated
that in cSLE, HMGB1 is released during NETosis, a
form of regulated cell death that occurs with neutrophils
(neutrophil extracellular traps, NET). As it has been
shown in this study, HMGB1 itself can also induce
NETosis and play an important role as a proinflamma-
tory mediator in cSLE [13].
According to previous studies, extracellular HMGB1
can amplify inflammation and enhance immune re-
sponses by interacting with the receptor for advanced
glycation end-products (RAGE) [14-20]. Although being
the first receptor demonstrated to bind HMGB1, some
members of the Toll-like receptor (TLR) family, such as
TLR2, TLR4, TLR9 and chemokine receptor C-X-C motif
receptor 4 (CXCR4) can bind HMGB1, too [21,22]. Trans-
membrane RAGE on monocytes, macrophages and other
cells is overexpressed in response to increasing concentra-
tion of its ligand HMGB1 and triggers inflammatory im-
mune response. Moreover, RAGE also exists in a soluble
form (sRAGE), which mitigates proinflammatory effects of
HMGB1, as shown by several studies [23-25]. It is there-
fore hypothesized that sRAGE binds RAGE-ligands, thus
acting as a “decoy” receptor [10].
Although data coming from clinical studies on chil-
dren are still very few in number, the presence of anti-
bodies to HMGB1 in JIA patients is documented [26,27].
Furthermore, recent research has showed high levels of
HMGB1 in synovial fluid in children with JIA correlating
with early onset of disease [28]. In addition, there is one
in vivo study in juvenile SLE patients that has shown a
correlation of HMGB1 with the disease activity regard-
less of nephritis presence [29]. Nevertheless, the role of
HMGB1 in JIA and cSLE has not been elucidated yet.
The aim of the present study was to determine the
presence of HMGB1 and sRAGE in sera and synovial
fluids in children with the different subtypes of JIA and
juvenile SLE, in order to assess their possible association
to clinical and serum markers for inflammation.
Methods
The study was designed as a prospective trial in which a
total of 144 children were enrolled. Among 97 patients
with newly diagnosed JIA, 35 children had polyarticular
type, 34 oligoarticular, and 27 systemic type of thedisease. All JIA patients fulfilled the ILAR diagnostic cri-
teria [30]. Furthermore, 19 children with newly diag-
nosed SLE were included in this study, each fulfilling the
American College of Rheumatology diagnostic criteria for
SLE [31], were included in this study. The control groups
included 28 children admitted to University Hospital
Centre Zagreb either for reasons not related to auto-
immunity or infectious diseases or for surgery not in con-
nection with any inflammatory diseases.
All the children were patients of Division of Pediatric
Rheumatology and Immunology, University Hospital
Centre Zagreb between 2007 and 2012. The study was ap-
proved by the Ethics Committee of the Zagreb University
School of Medicine and parental informed consent was
obtained for each child. For all patients, the following
routine laboratory tests were performed at the Department
of Clinical Laboratory Diagnostics, University of Zagreb
School of Medicine: erythrocyte sedimentation rate (ESR;
mm/hour), C-reactive protein levels (CRP; mg/l), α2-
globulins (%), γ-globulins (%), white blood cells count
(WBC; ×10^9/l), red blood cells (RBC; ×10^12/l), platelets
(PLT; ×10^9/l), hemoglobin (g/l), haematocrit (%). For pa-
tients with SLE autoantibodies, rheumatoid factor (RF),
and C3 and C4 complement components levels were also
analysed.
The blood samples were collected at the time of diagno-
sis, prior to the initiation of immunosuppressive treatment.
Seven patients did not receive any drug, while the rest of
the patients received nonsteroidal anti-inflammatory drugs.
The clinical and demographic data were recorded at the
time of the blood collection.
Venous blood was extracted in test tubes, which con-
tained an anticoagulant (EDTA), always between 9 and
10 a.m. Aliquots of the peripheral blood were centri-
fuged at 3500 rpm for 5 minutes at room temperature,
after which the supernatant is aspirated and stored in
kriotube (Nunc, Denmark) at −70°C until used. The
serum levels of alarmins were determined with commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kits: RAGE (R&D Systems, Minneapolis (MN),
USA) and HMGB1 (Shino-Test Corporation, Tokyo, Japan)
according to the manufacturer’s protocol. In addition, levels
of HMGB1 and sRAGE were determined by the same kits
in synovial fluid of 21 patients with oligoarticular and 7 pa-
tients with polyarticular when there was an indication for
evacuation of the synovial fluid.
All statistical analyses were performed with R statis-
tical programming language [32]. Differences between
groups of patients and the control group were analysed
by Kruskal-Wallis test, followed by a post-hoc test of pa-
tient groups against the control group [33]. Correlations
between variables were analysed with the Spearman’s
correlation test. P-values were adjusted with Bonferroni
method for multiple correlations between HMBG1 and
Table 1 Laboratory characteristics of children with juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and healthy controls
Characteristic p-value Juvenile idiopathic arthritis SLE (n = 19) Healthy controls (n = 28)
Systemic (n = 27) Oligoarticular (n = 34) Polyarticular (n = 35)
No. girls/boys - 7/20 27/7 27/8 14/5 20/8
Age, years - 9.9* (5.3-12.2) 2.9* (0.4-8.2) 6.4 (7.2-12.3) 14.4* (10.6-15.9) 6.2 (0.9-11.9)
HMGB1 (pg/ml) < 0.001 17402.50* (6400.57-80844.98) 3551.97* (108.89-10713.20) 4374.04* (273.50-93493.88) 8523.92* (3639.35-98296.88) 1149.70 (10.89-1976.47)
sRAGE (pg/ml) 0.006 1237.53* (46.42-6634.4) 2269.84 (225.60-5137.92) 1757.76 (230.40-4730.88) 924.45* (118.08-10569.20) 2275.80 (162.37-9206.38)
ESR (mm/h) < 0.001 86* (34–139) 17* (5–41) 40* (5–140) 57* (10–113) 7 (2–36)
CRP (mg/l) < 0.001 145.0* (6.9-264.0) 2.6 (0.2-25.7) 23.5* (0.1-156.0) 3.0 (0.6-25.0) 2.0 (0.1-6.8)
Hb (g/l) < 0.001 111* (80–128) 123 (99–144) 115* (75–140) 119 (78–140) 124 (110–145)
Hct (%) < 0.001 0.34* (0.23-0.56) 0.37 (0.29-0.43) 0.35 (0.24-0.43) 0.36 (0.22-0.42) 0.37 (0.32-0.52)
PLT, ×10^9/l < 0.001 397* (125–563) 391 (180–651) 363 (131–1038) 222 (122–568) 322 (176–414)
RBC, ×10^12/l < 0.001 4.17* (3.30-4.96) 4.51 (3.54-5.31) 4.26* (3.60-5.88) 4.13* (2.88-5.09) 4.63 (4.10-5.17)
WBC, ×10^9/l < 0.001 9.0* (6.4-29.9) 8.7* (4.0-17.1) 8.5* (3.5-27.0) 4.3 (2.0-19.4) 7.4 (2.5-9.7)
γ-globulin (%) < 0.001 17.0* (7.8-39.0) 14.2 (7.9-21.5) 21.8* (10.0-32.1) 22.2* (12.0-38.2) 13.9 (6.8-19.2)
α2-globulin (%) < 0.001 15.3* (11.2-26.3) 9.9* (5.2-16.7) 13.5* (12.9-19.2) 10.3* (8.0-17.7) 7.2 (4.9-14.3)
ANA (RU/ml) - 640 (100–10242)
anti-dsDNA (RU/ml) - 285 (68–2480)
C3 (mg/l) - 0.87 (0.32-1.74)
C4 (mg/l) - 0.13 (0.03-0.32)
*Significantly different from the healthy controls (Kruskal-Wallis test followed by a post-hoc test). ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; Hb = hemoglobin; Hct = haematocrit; PLT = platelets;
RBC = red blood cells; WBC = white blood cells; ANA = antinuclear antibody; anti-dsDNA = double stranded DNA antibodies; C3,C4 = complement components.
The data are summarized as median and range.
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<0.05 was considered as statistically significant. ROC
curves were constructed with the help of pROC package
for R statistical programming language [34]. On scatter-
plots, a smoothing line of locally weighted polynomial
regression (loess) was added [35]. Levels of HMGB1
serum in patients with hepatosplenomegaly and sero-
sitis (within the systemic JIA group) and with lupus
nephritis (within the SLE group) were compared with
patients without corresponding features within groups
by the Mann–Whitney U test.Results
Characteristics of patients with JIA, SLE and controls
Basic laboratory findings of the children with JIA, SLE
and healthy controls recruited in the study are shown in
Table 1.
During the initial examination, all the patients with
systemic-onset JIA presented with spiking fevers and skin
rash as well as high ESR, CRP and α2-globulins. Twelve
JIA patients presented with arthritis, at disease presenta-
tion. The rest of the patients with sJIA developed arthritis
later on while being hospitalised. Ten patients pre-
sented with lymphadenopathy, seven with hepatosple-
nomegaly and three with serositis. All the patients with
SLE were antinuclear antibody (ANA) positive, 87% had
double stranded DNA antibodies (anti-dsDNA), 63%
anti-Smith (Sm), 25% anti-SSA, 19% anti-SSB, 26% anti-
ribonucleoprotein (RNP) antibodies, 69% anti-histones,
but none of the patients were positive for rheumatoid factor
(RF). Six SLE patients were presented with constitutional
symptoms (fever, fatigue and weight loss), five with malar
rash, four with renal involvement, and two with polyarthri-
tis (data not show).Figure 1 Serum HMGB1 and sRAGE levels in patients and healthy con
receptor for advanced glycation endproducts (sRAGE) between children wi
lupus erythematosus (SLE) and healthy controls. Boxes represent the interq
median, and the whiskers extend to the most extreme data points (range).The inverse relationship of the HMGB1 to sRAGE in blood
samples from children with JIA and SLE taken at diagnosis
Serum levels of HMGB1 were significantly higher (P < 0.001)
in children with three major types of JIA and in children
with SLE, compared to healthy controls (Table 1).
As shown in Figure 1 the median serum HMGB1 levels
in children with systemic-onset JIA (17402 pg/ml) were 15
fold higher than those in control group (1149 pg/ml) and
were also significantly higher than those in children with
oligoarticular (3552 pg/ml), polyarticular (4374 pg/ml) or
SLE children (P < 0.05). There was no statistical difference
of the median serum HMGB1 levels between children with
oligoarticular and those with polyarticular onset JIA.
When the association between HMGB1 serum levels
and clinical characteristics of the disease was tested, we
found that systemic JIA children with hepatosplenome-
galy and serositis (27695,03 pg/ml) had significantly
higher HMGB1 serum levels compared with patients
without (12678,06 pg/ml) corresponding features (P <
0.001). Next, in a group with SLE children, we had four
patients presenting with lupus nephritis who also had
higher levels of HMGB1 (the median concentrations
were 36372,97 and 7013,95 pg/ml). The difference was
significant (P < 0.003).
At the same time, compared to the healthy children,
the children with all subgroups of JIA as well as children
with SLE were characterized by lower serum levels of
sRAGE, but the difference was significant only in pa-
tients with systemic-onset of JIA and in children with
SLE (Table 1).
The median concentrations of synovial fluid HMGB1
in patients with oligoarticular and polyarticular JIA
(43477,16 and 42630,17 pg/ml) were higher than in
serum (3551,97 pg/ml). In addition, the synovial fluid
level of sRAGE were lower in both oligoarticular JIAtrols. Serum levels of high mobility group box-1 (HMGB1) and soluble
th three major subgroups of juvenile idiopathic arthritis (JIA), systemic
uartile range, the thick horizontal line within the boxes represents the
Figure 2 The median concentrations of synovial fluid HMGB1 in patients with oligoarticular and polyarticular JIA. Significantly increased
high mobility group box-1 (HMGB1) and significantly reduced soluble receptor for advanced glycation endproducts (sRAGE) levels in synovial fluid
to blood samples from patients with oligoarticular (A) and polyarticular (B) juvenile idiopathic arthritis (JIA). In the box plots, the boxes represent
the interquartile range, the thick horizontal line within the boxes represents the median, and the whiskers extend to the most extreme data
points (range).
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respectively) than in serum (2269,84 and 1757,76 pg/ml,
respectively) (Figure 2).
Relationship between serum HMGB1 and sRAGE levels
and common inflammatory indicators of JIA and SLE
We were assessing the correlation of the HMGB1 and
sRAGE with the laboratory tests commonly used to
evaluate the disease activity of JIA and SLE.
In patients with JIA, regardless of the disease type, there
was statistically significant and positive correlation
between serum levels of HMGB1 and ESR (r = 0,574,
P < 0.001), CRP (r = 0,600; P < 0.001) and α2-globulin
(r = 0,533; P < 0.001) (Figure 3) while weak statisticallysignificant and negative correlation was found between
HMGB1 and Hb (r = − 0.362; P < 0.002), Hct (r = − 0.322;
P = 0.008) and RBC (r = − 0.285; P = 0.029).
In all patients with JIA, levels of sRAGE exhibit weak
but statistically significant negative correlation with the
levels of CRP (r = − 0,283; P = 0.010), and ESR (r = − 0,347;
P = 0.001).
Additionally, in children with SLE no association was
detected between HMGB1 or sRAGE to the commonly
used laboratory tests, but there was statistically signifi-
cant and positive correlation between sRAGE levels and
C4 complement component (r =0.47, P <0.045). Among
the study participants with systemic onset JIA, levels of
HMGB1 were significantly higher in patients with
Figure 3 Association of HMGB1 levels and ordinary acute-phase reactants in JIA children. The positive correlations between serum high
mobility group box-1 (HMGB1) levels and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), α2 globulins (α2) in 97 patients with
juvenile idiopathic arthritis (JIA) were found. Spearman’s correlation coefficients (r) and p-values are given in each chart’s top left corner, a locally
weighted polynomial regression line (loess) was super imposed on data points.
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without these clinical characteristics (27695,03 and
12678,06 pg/ml; P < 0.001). The CRP levels of systemic
JIA patients presenting with hepatosplenomegaly or
serositis were also significantly higher but HMGB1 was
more sensitive than CRP in detecting hepatosplenome-
galy or serositis in these patients, as shown by receiver
operating characteristics (ROC) curve assessment. The
area under the curve (AUC) for HMGB1 was 0.9941 and
for CRP was 0.7294 (mean with 95% confidence inter-
val). At the optimal cut-off value of 19595 pg/ml for
HMGB1, the diagnostic sensitivity was 94% and specifi-
city was 100%. At a cut-off concentration of 136 mg/l
CRP revealed a sensitivity of 64% and a specificity of
100% (Figure 4).
Discussion
Our study points to the deregulation of the alarmin sys-
tem in both JIA and juvenile SLE, demonstrated through
a significant increase of the serum levels of HMGB1,coupled with a decrease of its decoy receptor, soluble
RAGE. Although previous studies have implicated that
HMGB1 and sRAGE are involved in and considered as bio-
markers for a number of inflammatory diseases [14-16], re-
ports on JIA and juvenile SLE are quite scarce [13,26-29].
Antibodies to HMGB1 protein were detected in sera
of children with JIA although the relevance of that find-
ing still remains to be unveiled [26,27]. Moreover, recent
research has recorded high levels of HMGB1 in synovial
fluid in children with JIA correlating with early onset of
disease [28]. In addition, there is one in vivo study in
cSLE patients that has shown a correlation of HMGB1
with the disease activity regardless of the presence of
nephritis [29].
HMGB1, has also been evaluated as one of neutrophil
proteins in cSLE. Upon stimulation with anti-RNP anti-
bodies, mature SLE neutrophils while dying release
NETs containing much of HMGB1 [13]. The previous
observations implicated the role of HMGB1 on the JIA
and cSLE pathogenesis.
Figure 4 Receiveroperatingcharacteristiccurveof HMGB1 and
C-reactive protein (CRP) serum levels insystemiconset JIA. Among
the participants with systemic onset JIA, levels of HMGB1 and CRP were
significantly higher in patients with hepatosplenomegaly and serositis
compared to those without these clinical characteristics. HMGB1 was
more sensitive than CRP in detecting hepatosplenomegaly and serositis
in these patients, as shown by receiver operating characteristics (ROC)
curve. The area under the curve for HMGB1 was 0.9412, the mean ±
95% confidence, using a cut off value of 19595 pg/ml for HMGB1
and136 mg/l for CRP.
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HMGB1 levels in all subtypes of JIA patients versus
healthy controls, with the levels of HMGB1 particularly
elevated in children with sJIA. Furthermore, the levels of
HMGB1 were the highest in the subgroup of sJIA pa-
tients with hepatosplenomegaly or serositis, which is in
accordance with the known release of HMGB1 in acute
systemic inflammatory conditions such as sepsis [36].
Our data point to systemic release of HMGB1 as a pos-
sible trigger for uncontrolled inflammatory activity in
sJIA. The result of elevated serum HMGB1 in children
with SLE mirrors the situation in SLE adults, where
HMGB1 has been implicated in the pathogenesis and
manifestations of the disease. For example, HMGB1 is
often detectable in the skin lesions of patients with
chronic cutaneous lupus and may also act as a proin-
flammatory mediator in antibody-induced kidney dam-
age in SLE [37-39]. Since HMGB1 is an essential part of
the immune complexes in lupus and since the immune
complexes lead to immune activation via a pathway in-
volving RAGE, the elevation of HMGB1 and the simul-
taneous decline of sRAGE could favour HMGB1-RAGE
signalling as an important pathogenic mechanism.
Interestingly, our patients presenting with lupus neph-
ritis were also characterized by high levels of HMGB1,with statistical significance. It could be, therefore, pos-
sible that HMGB1 may act as a proinflammatory medi-
ator in kidney damage in SLE, as shown previously [40].
An inverse relationship between HMGB1 and its decoy
receptor, sRAGE, in the serum of children with JIA and
in SLE was not a surprise. Lower serum levels of sRAGE
are in the line with a report on decreased levels of
sRAGE in chronic inflammatory diseases [24,25]. Al-
though it is still not clear whether the high levels of
HMGB1 cause diminishing level of sRAGE by the con-
sumption of this soluble receptor or whether low levels
of sRAGE strengthen proinflammatory effect of
HMGB1, a study by Schaper et al. demonstrated that the
increased serum levels of HMGB1 in patients with SLE
lead to the consumption of sRAGE during the inflam-
matory process [41]. In contrast to these studies, there is
one work which has shown higher level of sRAGE in ac-
tive SLE [42]. The result disparity is possible due to a
small number of subjects, only 10, and as pointed out by
the authors of the aforementioned study, the cause may
be in medication use as well.
Further, we aimed to investigate the potential role of
HMGB1 as a marker of disease activity with JIA and
SLE serving as a model of acute inflammation. It is
established that ESR and CRP, classic markers of inflam-
mation are raised in sJIA, but it is not specific for the
detection of sJIA activity. In our paper a significant posi-
tive correlation was observed between HMGB1 and
ESR, CRP and α2 globulin which suggests that the meas-
urement of serum HMGB1 protein levels in serum may
be a useful tool in the evaluation of sJIA patients, at least
in acute inflammation. This is corroborated by the fact
that although the CRP levels in systemic JIA patients
presenting with hepatosplenomegaly or serositis were
very high, HMGB1 was a more sensitive indicator (a
diagnostic sensitivity for HMGB1 was 94% while for
CRP was 64%). It is well known that HMGB1 is released
at the site of joint inflammation and that the injection of
HMGB1 into a normal joint causes development of arth-
ritis [43-45]. In that context, our finding of increased
amounts of HMGB1 in inflamed joints of children with
oligoarticular and polyarticular JIA led us to the hypoth-
esis that the another possible origin of HMGB1 in JIA
could have been the inflamed joints and that serum
HMGB1 was not synthesised only by the circulating
leukocytes. However, a further research, aimed at eluci-
dating the exact role of the alarmin system, is obviously
called for. A possible shortcoming of our study was the
small number of SLE patients. However we would like
to point out that we were dealing with the disease
which in not considered common among pediatric pa-
tients. For instance, the overall annual incidence rate of
Croatian children with SLE varied from 1 to 15 per million
children in the last 20 years [46].
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We believe that our description of an inverse relation-
ship of increased serum levels of HMGB1 and decreased
serum levels of sRAGE in blood samples taken at diag-
nosis indicates that inflammation triggered by alarmins
plays a role in pathogenesis of JIA and juvenile SLE. Fur-
thermore, the results presented here suggest that alarmin
may be a potential therapeutic target for immunotherapy
of JIA and SLE, but also suggest that HMGB1 may be a
valuable laboratory biomarker. Further studies in longitu-
dinally collected blood samples over time from patients
may reveal whether HMGB1 could be a valuable bio-
marker even more sensitive and specific than other avail-
able indicators of inflammation.
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